# US 2008/0305089 A1 · Pharmaceutical Composition for Protection from Allergies and Inflammatory Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305089 A1
- Document ID: US20080305089A1
- Status: Published application
- Kind: A1
- Application number: 12/041,553
- Filed: 2008-03-03
- Published: 2008-12-11
- Earliest claimed: 2007-03-02
- Assignees: Protectimmun GmbH
- Inventors: Albrecht Bufe; Otto Holst; Harald Renz; Erika von Mutius; Johann Bauer; Nicole Blumer; Jennifer Debarry; Markus Ege; Susanne Friedrich; Holger Garn; Soren Gatermann; Anna Hanuszkiewicz; Holger Heine; Michael Wegmann
- Web page: https://patentgrep.com/patent/US20080305089A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition which includes naturally occurring, non-transgenic isolated bacteria from the group of Lactococcus and Acinetobacter or fragments thereof or mixtures thereof, to such a bacterium as a medicament for the prevention and/or treatment of allergic or chronic inflammatory disorders and to a process for producing this composition.

## Claims

### Claim 1

A pharmaceutical composition comprising naturally occurring, non-transgenic, isolated bacteria selected from the group consisting of Lactococcus and Acinetobacter or fragments thereof or a mixture thereof and, where appropriate, a pharmaceutically acceptable carrier for the prevention and/or treatment of allergic or chronic inflammatory disorders selected from IgE-dependent type I allergies or type IV allergies, and chronic inflammatory cutaneous disorders or autoimmune diseases.

### Claim 2 (depends on 1)

The pharmaceutical composition as claimed in claim 1, which is in the form of an aerosol, aqueous solution, suspension, lyophilizate or powder.

### Claim 3 (depends on 1)

The composition of claim 1, comprising a combination of Lactococcus and Acinetobacter in a mixing ratio of from 5:95 to 95:5.

### Claim 4 (depends on 1)

The composition as claimed in claim 1, wherein the bacteria are selected from Lactococcus lactis and Acinetobacter lwoffii.

### Claim 5 (depends on 1)

The composition as claimed in claim 1, wherein the bacteria are in the vital or killed state.

### Claim 6 (depends on 1)

The composition as claimed in claim 1 for oral, nasal, conjunctival, inhalational, subcutaneous, intra-articular, intraperitoneal, rectal or vaginal administration.

### Claim 7 (depends on 1)

The composition as claimed in claim 1, wherein said composition has effects for the prevention and/or treatment of hay fever, food allergies, asthma, neurodermatitis, atopic dermatitis, contact eczema, psoriasis, type 1 or 2 diabetes, multiple sclerosis, rheumatoid arthritis, thyroid disorders such as Hashimoto's thyroiditis and Graves' disease.

### Claim 8 (depends on 1)

The composition as claimed in claim 1, which is suitable for the prevention of allergic or chronic inflammatory disorders in babies or pregnant women who, owing to a positive family history, have a distinctly increased risk of developing such a disorder, and/or is suitable for the prevention or treatment of allergic or chronic inflammatory disorders in babies or pregnant women who show the first manifestations of such a disorder.

### Claim 9 (depends on 1)

The composition as claimed in claims 1, further comprising at least one bacterium selected from the group consisting of Micrococcus spp., Planococcus spp., Staphylococcus spp., Streptococcus spp., Lactococcus spp., Aerococcus spp., Gemella spp., Enterococcus spp., Bacillus spp., Clostridium spp., Micromonospora spp., Lactobacillus spp., Listeria spp., Erysipelothrix spp., Acinetobacter spp., Leuconostoc spp., Corynebacterium spp., Clavibacter spp., Brevibacterium spp., Propionibacterium spp., Arthrobacter spp., Curtobacterium spp., Microbacterium spp., Aureobacterium spp., Cellulomonas spp., Agromyces spp., Eubacterium spp., Pseudomonas spp., Xantomonas spp., Frateuria spp., Zoogloea spp., Escherichia spp., Enterobacter spp., Pantoea spp., Erwinia spp., Citrobacter spp., Klebsiella spp., Proteus spp., Serratia spp., Actinomyces spp., Streptomyces spp., Nocardia spp., Mycobacterium spp., Absidia spp., Wallemia spp., Eurotium spp., Acremonium spp., Aspergillus spp., Penicillium spp., Cladosporium spp., Cephalosporium spp., Fusarium spp., Mucor spp., and Trichoderma spp., or in combination with trichothecenes, fumonisins, gliotoxin, ochratoxins, patulin, aflatoxins or fragments thereof or mixtures thereof.

### Claim 10 (depends on 1)

A process for producing a pharmaceutical composition as claimed in claim 1, comprising the steps:
a isolating a natural, non-transgenic bacterium selected from the group consisting of Lactococcus and Acinetobacter,
b growing of the isolated bacterium in culture,
c where appropriate killing and/or lyophilizing the bacterium,
d where appropriate fragmentating the bacterium, and
e mixing the vital or, where appropriate, killed, lyophilized or fragmented bacterium with a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The process as claimed in claim 10, where the pharmaceutically acceptable carrier is selected from the group consisting of water, alcohol, a buffer solution or salt solution, a hydroalcoholic mixture, pharmaceutically acceptable powder, ground silicate, starch, cellulose and cellulose derivatives.

### Claim 12

A method for prevention and/or treatment of allergic or chronic inflammatory disorders selected from IgE-dependent type I allergies or type IV allergies, and chronic inflammatory cutaneous disorders or autoimmune diseases comprising administering to a subject in need thereof a pharmaceutical composition comprising naturally occurring, non-transgenic, isolated bacteria selected from the group consisting of Lactococcus and Acinetobacter or fragments thereof or a mixture thereof.

### Claim 13 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition is in the form of an aerosol, aqueous solution, suspension, lyophilizate or powder.

### Claim 14 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition comprises a combination of Lactococcus and Acinetobacter in a mixing ratio of from 5:95 to 95:5.

### Claim 15 (depends on 12)

The method as claimed in claim 12, wherein said bacteria are selected from Lactococcus lactis and Acinetobacter lwoffii.

### Claim 16 (depends on 12)

The method as claimed in claim 12, wherein said bacteria are in the vital or killed state.

### Claim 17 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition is for oral, nasal, conjunctival, inhalational, subcutaneous, intra-articular, intraperitoneal, rectal or vaginal administration.

### Claim 18 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition has effects for the prevention and/or treatment of hay fever, food allergies, asthma, neurodermatitis, atopic dermatitis, contact eczema, psoriasis, type 1 or 2 diabetes, multiple sclerosis, rheumatoid arthritis, thyroid disorders such as Hashimoto's thyroiditis and Graves' disease.

### Claim 19 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition is suitable for the prevention of allergic or chronic inflammatory disorders in babies or pregnant women who, owing to a positive family history, have a distinctly increased risk of developing such a disorder, and/or is suitable for the prevention or treatment of allergic or chronic inflammatory disorders in babies or pregnant women who show the first manifestations of such a disorder.

### Claim 20 (depends on 12)

The method as claimed in claim 12, wherein said pharmaceutical composition further comprises at least one bacterium selected from the group consisting of Micrococcus spp., Planococcus spp., Staphylococcus spp., Streptococcus spp., Lactococcus spp., Aerococcus spp., Gemella spp., Enterococcus spp., Bacillus spp., Clostridium spp., Micromonospora spp., Lactobacillus spp., Listeria spp., Erysipelothrix spp., Acinetobacter spp., Leuconostoc spp., Corynebacterium spp., Clavibacter spp., Brevibacterium spp., Propionibacterium spp., Arthrobacter spp., Curtobacterium spp., Microbacterium spp., Aureobacterium spp., Cellulomonas spp., Agromyces spp., Eubacterium spp., Pseudomonas spp., Xantomonas spp., Frateuria spp., Zoogloea spp., Escherichia spp., Enterobacter spp., Pantoea spp., Erwinia spp., Citrobacter spp., Klebsiella spp., Proteus spp., Serratia spp., Actinomyces spp., Streptomyces spp., Nocardia spp., Mycobacterium spp., Absidia spp., Wallemia spp., Eurotium spp., Acremonium spp., Aspergillus spp., Penicillium spp., Cladosporium spp., Cephalosporium spp., Fusarium spp., Mucor spp., and Trichoderma spp., or in combination with trichothecenes, fumonisins, gliotoxin, ochratoxins, patulin, aflatoxins or fragments thereof or mixtures thereof.
